Treatment of diabetes: Crossing to the other side.
Type 2 diabetes mellitus affects nearly four hundred million people worldwide, and one of its major complications is cardiovascular disease. The evaluation of the effectiveness and safety of antidiabetic medication has been a challenging issue. Large clinical trials of new antidiabetic medications have used the non-inferiority approach to ensure primary safety of the drug before its incorporation into clinical practice. Currently, the trend is to prove superiority, that is, to prove that the new drug has additional beneficial effects to those of standard medications. In this review, we present the results of recent clinical trials on type 2 diabetes mellitus medications and outline what can be anticipated from ongoing clinical trials.
Hippokration Hospital, University of Athens, 1st Department of Cardiology, Athens, Greece.
Nikitas P
NP
Skliros
Hippokration Hospital, University of Athens, 1st Department of Cardiology, Athens, Greece. Electronic address: cvlachop@otenet.gr.
Charalambos
C
Vlachopoulos
Hippokration Hospital, University of Athens, 1st Department of Cardiology, Athens, Greece.
Dimitrios
D
Tousoulis
D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents
Antidiabetic drugs; Cardiovascular disease; Cardiovascular outcome trials; Cardiovascular safety; Type 2 diabetes mellitus